Notice/News
Notice/News
Number
Title
Date
1
[IR Pharm] Genome Editing’s New Paradigm (1): From Statistics to Mechanism—FDA Shake‑Up Creates a Once‑in‑a‑Generation Chance for ToolGen
2026.05.04
2
[Notice] U.S. Patent Registration Certificate (US 12,612,632 / US 12,612,633 / US 12,612,634)
2026.04.28
3
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.04.28
4
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.04.21
5
[Notice] U.S. CRISPR RNP Patent Granted_US 12,606,832 B2
2026.04.21
6
[Notice] The Priority Phase of Interference No. 106,126 between ToolGen and the Broad Institute has resumed
2026.03.31
7
[Notice] March 26, 2026 PTAB Decision: Summary and Outlook
2026.03.30
8
[edaily] “ToolGen’s Yoo Jong‑sang Says CRISPR‑Cas9 Patent Battle Heats Up in H2, With Rising Pressure for a Three‑Party Deal”
2026.03.26
9
[Notice] ToolGen to Form Science Advisory Board (SAB)
2026.03.25
10
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.03.18
11
[Financial Economy Plus] CRISPR, Part 4: Opening Act of a ‘Licensing Boom’—ToolGen Steps Beyond a Royalty Hub to the Center of Global Collaboration
2026.03.02
12
[Financial Economy Plus] CRISPR, Part 3: Platform Advantage — “Time Is on ToolGen’s Side” as Protracted Disputes Prolong Monopoly Terms
2026.03.01
13
[Financial Economy Plus] CRISPR, Part 2: “Find Biotech’s ARM” — The Power of the ‘Standard Technology’ Dominating Gene Editing
2026.02.28
14
[Financial Economy Plus] CRISPR, Part 1: From Probability to Design as FDA Redraws the Gene‑Editing Profit Formula
2026.02.27
15
[Finance Economy Plus] “Patents are the sword; royalties are the shield” — ToolGen declares 2026 its inaugural year for monetizing gene‑editing “scissors.”
2026.02.18